In a major step forward for regenerative medicine in Southeast Asia, Vega Stem Cell is pleased to announce a strategic alliance with AGEM Bio (Singapore) and the Thailand Institute of Scientific and Technological Research (TISTR). This trilateral collaboration combines advanced immunotherapy platforms, clinical stem cell expertise, and scientific oversight to accelerate the development of next-generation cell therapies in Thailand.
The partnership aims to adapt, validate, and implement AGEM Bio’s cutting-edge immune cell technologies for clinical use, including cancer-targeting allogeneic immune cells and macrophage-based “cleaner” cells designed to reshape tumor environments and combat aggressive cancers. These innovations have already demonstrated strong preclinical outcomes and success in compassionate-use veterinary applications. Human clinical trials are expected to begin in Thailand by early 2026, with glioblastoma, a severe form of brain cancer, selected as the first targeted indication.
AGEM Bio, a biotech company spun out of research at the National University of Singapore (NUS), is known for its proprietary macrophage and natural killer (NK) cell platforms. These therapies are engineered to overcome the limitations of conventional cancer treatments and have gained international attention for their novel approach to immuno-oncology.
The collaboration will begin with a phase of technology transfer and feasibility assessment, paving the way for early clinical deployment. TISTR will play a central role in ensuring regulatory compliance, local validation, and alignment with Thailand’s national R&D strategies, facilitating smooth clinical integration.
Vega Stem Cell contributes a strong foundation of clinical experience in regenerative medicine, offering mesenchymal stem cell (MSC) therapies for orthopedic, chronic, and age-related conditions. By integrating AGEM Bio’s oncology-focused immune cell platforms with Vega’s regenerative protocols, the collaboration will enable multi-functional treatment strategies that combine immune modulation, inflammation control, and tissue regeneration.
This alliance also supports broader goals of making advanced cell therapies more accessible and scalable in Thailand, positioning the country as a future regional hub for biomedical innovation. With increasing demand for regenerative treatments among local patients and international medical tourists, Thailand is uniquely placed to adopt and lead the next wave of global biologics and cell therapy.
About AGEM Bio
AGEM Bio Pte Ltd is a Singapore-based biotech company pioneering engineered immune cell therapies, including natural killer (NK) and macrophage-based platforms. Founded by scientists from the National University of Singaporeand backed by SGInnovate, AGEM Bio focuses on creating off-the-shelf immunotherapies for difficult-to-treat cancers.
About TISTR
The Thailand Institute of Scientific and Technological Research (TISTR) operates under the Ministry of Higher Education, Science, Research and Innovation. It serves as a national platform for applied R&D, regulatory science, and the advancement of biotechnology in Thailand.
About Vega Stem Cell
Vega Stem Cell is a Bangkok-based clinic offering advanced stem cell and regenerative medicine therapies. Committed to safety and scientific rigor, Vega specializes in the use of mesenchymal stem cells for treating chronic diseases, orthopedic injuries, and age-related degeneration.
Contact Information:
Vega Medical Services
3/6, The Primary 101, Soi Lad Phrao 101
Lad Phrao Road, Khlong Chan
Bang Kapi District, Bangkok 10240
Thailand
Email: vegastemcell@gmail.com
Tel & WhatsApp: +66 (0) 86 691 6915
Website: www.vegastemcell.com